Roche Challenges Natco's Risdiplam Launch in Supreme Court Patent Showdown

NEW DELHI – The high-stakes battle over patent rights and access to life-saving medication has escalated to India's highest judicial body. Swiss pharmaceutical giant F Hoffmann-La Roche AG has approached the Supreme Court, challenging a Delhi High Court order that greenlit Indian drugmaker Natco Pharma to manufacture and sell a generic version of Risdiplam, a critical drug for treating Spinal Muscular Atrophy (SMA). The Chief Justice of India has agreed to an urgent listing of the matter, setting the stage for a landmark hearing that could redefine the contours of pharmaceutical patent litigation in the country.

The dispute centres on Roche's Indian Patent IN'397, which covers compounds for treating SMA and is valid until 2035. Roche alleges that Natco's generic product is a direct infringement of this patent. However, the legal journey to this point has seen Indian courts prioritize the vulnerability of the patent and public interest, a stance that the Supreme Court will now scrutinize.

The High Court's Refusal to Interfere

Roche's appeal to the Supreme Court follows a significant setback at the Delhi High Court. On October 9, a Division Bench comprising Justice C Hari Shankar and Justice Ajay Digpaul dismissed Roche's appeal for an interim injunction against Natco. This decision upheld a prior ruling by a Single Judge, effectively allowing Natco to continue its production and sale of generic Risdiplam.

The crux of the High Court's decision lay in Natco's formidable defense strategy. Invoking Section 107(1) of the Patents Act, 1970, Natco did not merely deny infringement but mounted a credible challenge to the very validity of Roche's patent. This statutory defense allows an accused infringer to argue that the patent in question should not have been granted in the first place.

Natco's challenge was twofold, arguing that Roche's patent was invalid on grounds of:

1. Lack of Novelty under Section 64(1)(e).

2. Obviousness (lack of inventive step) under Section 64(1)(f).

The Division Bench was particularly persuaded by the argument of obviousness. It found that Natco had presented a substantial case that Roche's patented invention was an obvious development in light of existing prior art. The court specifically referenced "Compound 809 in WO'916/US'955" as a pre-existing compound that rendered the invention of Risdiplam obvious to a person skilled in the art.

In its ruling, the bench affirmed the Single Judge's detailed analysis, stating there was “no reason to interfere with the findings of the learned Single Judge that Risdiplam is vulnerable to invalidity in terms of Section 64(1)(f) of the Patents Act, as being obvious vis-à-vis prior art...” The court also noted that Roche had not made a sufficient case for interference under the established principles of Wander Ltd. v. Antox India P. Ltd. , which limit an appellate court's scope to overturn a lower court's discretionary grant or refusal of an injunction.

Balancing Patent Rights and Public Access

This case transcends a simple commercial dispute, delving into the delicate balance between incentivizing pharmaceutical innovation through robust patent protection and ensuring that life-saving medicines are accessible and affordable to the public. The Single Judge, in an earlier ruling, had explicitly highlighted this tension, emphasizing the importance of affordability for a drug treating a debilitating condition like SMA. The court acknowledged the high price of Roche's patented drug, which put it beyond the reach of most Indian patients.

Natco Pharma has since launched its generic version at an MRP of ₹15,900, a fraction of the cost of the innovator drug, and has announced patient support programs to offer further discounts. This move underscores the public health dimension that has heavily influenced the judiciary's approach thus far.

The High Court's decision to deny an injunction, based on the credible challenge to the patent's validity, reflects a growing trend in Indian jurisprudence. Courts are increasingly willing to look past the mere registration of a patent and assess its strength on a prima facie basis, especially when a credible invalidity defense is raised and significant public interest is at stake.

Implications for the Pharmaceutical and Legal Sectors

The Supreme Court's decision to hear the appeal is a critical development with far-reaching implications. The outcome will be closely watched by both innovator and generic pharmaceutical companies operating in India.

For innovator companies like Roche, a reversal of the High Court's order would strengthen the sanctity of granted patents and make it more difficult for generic competitors to "launch at risk" before a patent's validity is fully adjudicated. It would reinforce the patent holder's right to an injunction as a primary remedy against perceived infringement.

For generic manufacturers like Natco, an affirmation of the High Court's decision would embolden the use of the "credible challenge" or "vulnerability of patent" defense. It would confirm that a well-argued challenge to a patent's validity, particularly on grounds of obviousness, can be sufficient to ward off a preliminary injunction, thereby allowing generics to enter the market sooner.

The legal community is focused on how the Supreme Court will interpret the threshold for what constitutes a "credible challenge" to a patent's validity at the interim stage. The Court’s analysis of Section 107(1) of the Patents Act and its interplay with the criteria for granting temporary injunctions will set a binding precedent for all lower courts.

As the market reacts to these legal manoeuvres—Natco Pharma's shares dropped 3.5% following the news of the Supreme Court appeal—all eyes are on the apex court. Its forthcoming decision will not only determine the fate of Risdiplam in India but will also send a powerful signal about the future of intellectual property enforcement and public health considerations in one of the world's most vital pharmaceutical markets.